Vaccitech Appoints Joseph Scheeren, PharmD, to its Board of Directors
Mar 22, 2021

Oxford, UK – Vaccitech Ltd (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announces the appointment of Joseph Scheeren, PharmD, as an independent director to its Board of Directors (the “Board”). Dr. Scheeren succeeds Thomas Evans, M.D., who continues in his role as Vaccitech’s Chief Scientific Officer.

“Dr. Scheeren is a distinguished and accomplished former pharmaceutical executive who can bring additional global research and development and drug commercialisation insights to our Board,” said Robin Wright, Chairman of the Board of Vaccitech. “His appointment also takes the number of independent directors on the Board to five to align with corporate best practices. Dr. Thomas Evans will retire from the Board after four years of helping to establish Vaccitech’s presence at the forefront of vaccine and immunotherapy development. He will continue driving our vision forward as Vaccitech’s Chief Scientific Officer. The Board of Directors and I welcome Dr. Scheeren and thank Tom for his contributions to the Board.”

Dr. Scheeren said, “Vaccitech’s T cell immunotherapy platform is aiming to address a number of globally challenging infectious diseases and cancer. I look forward to contributing my expertise in regulatory science, my familiarity with global marketplaces, and the experiences I have gained as the Chief Executive Officer of a fast-paced growth company to help steer Vaccitech toward successful development of its promising programs.”

Dr. Scheeren is a global expert in research and development and regulatory affairs in the pharmaceutical industry. He recently retired from his role as President and Chief Executive Officer of Critical Path Institute, a non-profit organization that validates tools to accelerate drug development. Prior to this, he held various senior roles at Bayer AG for 15 years, including as head of global regulatory affairs. He also held numerous executive positions at Aventis Pharmaceuticals, Roussel UCLAF, Ares Serono and Les Laboratoires Servier. He currently serves as a director on several boards of non-profit organizations, is an adjunct Professor of Regulatory Science at Peking University, Beijing, and is a lecturer at Yale University. Dr Scheeren earned his PharmD at the University of Leiden, Leiden, the Netherlands, School of Pharmacy.

Media contacts:

Katja Stout, Scius Communications (EU)

Direct: +44 (0) 7789435990

Email: katja@sciuscommunications.com

Ryo Imai / Robert Flamm, Ph.D. (US), Burns McClellan, Inc.

212-213-0006 ext. 315 / 364

Email: Rimai@burnsmc.com / rflamm@burnsmc.com

Henry Hodge, Vaccitech

Direct: +44 (0) 7533 421 442

Email: henry.hodge@vaccitech.co.uk